Nuwellis CEO leads heart failure technology company into new sectors
By Todd Nelson, Special to the Star Tribune May 2, 2021 2:00pm Text size Copy shortlink:
Nuwellis CEO Nestor Jaramillo Jr. said nearly $21 million in new financing is helping the company expand commercialization of its novel ultrafiltration therapy system and a new broader application in treating pediatric and critical care patients in addition to its historical use as a heart failure treatment.
The company, formerly known as CHF Solutions, last week announced its name change to Nuwellis Inc., to emphasize it no longer exclusively focuses on heart failure.
The fundraising round, announced in March, exceeded its target and attracted the health care investors Nuwellis was seeking, Jaramillo said.